Curis, Inc. — 2011 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2011; filed February 29, 2012. Curis is a clinical-stage cancer drug developer whose revenue depends primarily on collaboration milestones and royalties. Erivedge (vismodegib), developed and commercialized by Genentech/Roche, was FDA-approved for advanced basal cell carcinoma in January 2012, after year-end.
Financial results and liquidity
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Revenue | $14.76 million | $16.00 million |
| Research and development expense | $13.69 million | $11.37 million |
| General and administrative expense | $8.27 million | $10.26 million |
| Operating loss | $7.20 million | $5.64 million |
| Net loss | $9.86 million | $4.44 million |
| Net loss per share | $0.13 | $0.06 |
| Cash, cash equivalents and marketable securities at year-end | $37.72 million | $40.38 million |
| Working capital at year-end | $34.72 million | $37.61 million |
- FY 2011 revenue fell 8%, and 97% came from Genentech. The $14 million of 2011 license revenue reflected acceptance of the Erivedge U.S. NDA and European MAA for review; it was not the separate $10 million milestone earned upon FDA approval in January 2012.
- Net cash used in operations was $4.56 million, compared with $1.63 million in 2010. Investing activities provided $9.78 million, principally reflecting net sales of marketable securities; financing activities provided $2.08 million.
- No conventional borrowing is identified in the balance sheet. Total liabilities were $8.30 million, including a $4.36 million warrant liability, which increased by $2.76 million and materially increased reported net loss. The filing reports no off-balance-sheet arrangements.
- Gross margin is not a meaningful disclosed performance measure for this collaboration- and milestone-driven business; product sales and royalties had not yet generated reported revenue.
Material changes and unusual items
- Revenue was lower than in 2010, when it included $11 million of Debiopharm milestones and $4 million from a Micromet settlement. FY 2011 instead included $14 million of Genentech milestones.
- R&D expense increased 20%, reflecting higher spending on CUDC-101 and the newly selected CUDC-907 candidate, partly offset by lower spending on other pipeline programs. G&A expense declined 19%, principally due to lower legal costs, including the absence of much of 2010’s Micromet arbitration expense.
- Fourth-quarter 2011 revenue was $14.09 million and net income was $6.06 million, driven by recognition of the $14 million Genentech milestone revenue. The full-year result remained a net loss.
- The January 2012 FDA approval earned Curis an additional $10 million milestone, with royalties due on future sales. Curis is also eligible for an additional milestone if Erivedge receives European authorization.
Programs, outlook and key risks
- Erivedge’s pivotal Phase II study reported response rates of 43% in locally advanced BCC and 30% in metastatic BCC; median response duration was 7.6 months in both cohorts. The label carries a boxed warning for fetal harm. Genentech/Roche control development, manufacturing and commercialization, so Curis’s royalties and future prospects depend substantially on their execution and product uptake.
- Curis planned to continue developing CUDC-101, including a Phase I combination study in HPV-negative head and neck cancer and an oral formulation. It expected to file an IND for CUDC-907 in the second half of 2012, subject to successful preclinical and formulation work. These programs remained early-stage, with efficacy in humans unproven.
- Debiopharm advanced Debio 0932 into a Phase Ib expansion study in early 2012. Curis’s next potential milestone depends on Debiopharm advancing the program into Phase II and treating the specified patient threshold.
- Management estimated year-end 2012 cash, cash equivalents and marketable securities of $23–27 million, excluding potential collaborator payments; projected 2012 R&D expense of $16–20 million and G&A expense of $10–12 million. The company expected existing resources, including the January 2012 milestone, to support current and planned operations into the second half of 2013. These are estimates, not assurances.
- Curis had no current research funding under its Genentech or Debiopharm agreements and expected continuing operating losses. Additional financing may be needed; equity financing could dilute shareholders, and failure to obtain funding could delay or curtail development. Other principal risks include clinical and regulatory uncertainty, partner dependence, competition, manufacturing and supply reliance, intellectual-property challenges, and stock-price volatility.
- For CUDC-907, the Leukemia & Lymphoma Society agreed to fund about 50% of direct development costs, up to $4 million, subject to conditions; Curis may owe payments of up to $10 million under specified partnering or commercialization circumstances.
Most important facts for investors to verify
- Erivedge launch performance, sales, royalty rates actually earned, and any EMA decision or additional milestone.
- Cash use against the $23–27 million 2012 ending-cash forecast, the stated runway, and the timing and terms of any new financing or collaboration.
- Clinical and regulatory progress for CUDC-101, CUDC-907 and Debio 0932, including trial results, IND timing and partner decisions.
- The warrant liability’s valuation and potential dilution, as well as changes in shares outstanding and use of the $20 million at-the-market sales facility.
- Curis reported effective disclosure controls and internal control over financial reporting; its independent auditor issued unqualified opinions on the financial statements and internal controls. No material legal proceedings were reported.